» Articles » PMID: 39294495

Pharmacological Restriction of Genomic Binding Sites Redirects PU.1 Pioneer Transcription Factor Activity

Abstract

Transcription factor (TF) DNA-binding dynamics govern cell fate and identity. However, our ability to pharmacologically control TF localization is limited. Here we leverage chemically driven binding site restriction leading to robust and DNA-sequence-specific redistribution of PU.1, a pioneer TF pertinent to many hematopoietic malignancies. Through an innovative technique, 'CLICK-on-CUT&Tag', we characterize the hierarchy of de novo PU.1 motifs, predicting occupancy in the PU.1 cistrome under binding site restriction. Temporal and single-molecule studies of binding site restriction uncover the pioneering dynamics of native PU.1 and identify the paradoxical activation of an alternate target gene set driven by PU.1 localization to second-tier binding sites. These transcriptional changes were corroborated by genetic blockade and site-specific reporter assays. Binding site restriction and subsequent PU.1 network rewiring causes primary human leukemia cells to differentiate. In summary, pharmacologically induced TF redistribution can be harnessed to govern TF localization, actuate alternate gene networks and direct cell fate.

Citing Articles

Alternative Approach to Sequence-Specific Recognition of DNA: Cooperative Stacking of Dication Dimers─Sensitivity to Compound Curvature, Aromatic Structure, and DNA Sequence.

Paul A, Terrell J, Farahat A, Ogbonna E, Kumar A, Boykin D ACS Chem Biol. 2025; 20(2):489-506.

PMID: 39920086 PMC: 11851451. DOI: 10.1021/acschembio.4c00800.


Mastering fate: Redistributing a pioneer protein to rewrite leukemia's script.

Huang Y, de Bock C Hemasphere. 2025; 9(1):e70084.

PMID: 39850646 PMC: 11754763. DOI: 10.1002/hem3.70084.


PU.1 eviction at lymphocyte-specific chromatin domains mediates glucocorticoid response in acute lymphoblastic leukemia.

Beck D, Cao H, Tian F, Huang Y, Jiang M, Zhao H Nat Commun. 2024; 15(1):9697.

PMID: 39516193 PMC: 11549222. DOI: 10.1038/s41467-024-54096-2.


Pharmacologic Blockade of a Pioneer Transcription Factor.

Cermakova K, Hodges H Cancer Res. 2024; 84(24):4124-4125.

PMID: 39476188 PMC: 11866459. DOI: 10.1158/0008-5472.CAN-24-3957.

References
1.
Fu X, Jeselsohn R, Pereira R, Hollingsworth E, Creighton C, Li F . FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016; 113(43):E6600-E6609. PMC: 5087040. DOI: 10.1073/pnas.1612835113. View

2.
Cirillo L, Zaret K . Specific interactions of the wing domains of FOXA1 transcription factor with DNA. J Mol Biol. 2006; 366(3):720-4. PMC: 1793999. DOI: 10.1016/j.jmb.2006.11.087. View

3.
Antony-Debre I, Paul A, Leite J, Mitchell K, Kim H, Carvajal L . Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017; 127(12):4297-4313. PMC: 5707147. DOI: 10.1172/JCI92504. View

4.
Xie Z, Bailey A, Kuleshov M, Clarke D, Evangelista J, Jenkins S . Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021; 1(3):e90. PMC: 8152575. DOI: 10.1002/cpz1.90. View

5.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View